Mackay Medical University
11 imported, source-linked research records. Open-access records.
11 matching research records
Topic: Canagliflozin and SGLT2. Only records linked to Mackay Medical University are included. Historical ingestion is still running; these are imported records, not a count of all research worldwide.
Showing 1–11 of 11 matching records. Counts update as records arrive.
The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study
December 29, 2025 · 0 citations · Open access
Open original record →ALDH2 Enzyme Deficiency in Diabetic Cardiomyopathy
June 9, 2025 · 8 citations · Open access
Open original record →Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors
May 16, 2025 · 10 citations · Open access
Open original record →2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.
September 1, 2024 · 7 citations · Open access
Open original record →Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis
May 22, 2024 · 18 citations · Open access
Open original record →Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study
April 9, 2024 · 11 citations · Open access
Open original record →Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
December 3, 2023 · 7 citations · Open access
Open original record →Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
October 12, 2022 · 27 citations · Open access
Open original record →Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
July 28, 2021 · 112 citations · Open access
Open original record →Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study
August 19, 2020 · 13 citations · Open access
Open original record →The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
April 1, 2019 · 204 citations · Open access
Open original record →